Prostate cancer patients who have mutations in the DNA repair pathway (such as BRCA1, BRCA2, ATM, RAD51D and PALB2) have been shown to be significantly more likely to have advanced disease than patients without these mutations. Here, ATM is linked to prostate carcinoma.